Thomas Fagan Jr.

Vice President, U.S. Alzheimer’s Disease Commercial, Eisai Inc.

Thomas D. Fagan, Jr., serves as Vice President, U.S. Alzheimer’s Disease Commercial, for Eisai Inc. In this role, he is responsible for leading the commercial strategy for the company’s Alzheimer’s disease (AD) business in the U.S. He also serves as a member of the company’s Executive Committee for the Americas.

Mr. Fagan has an extensive leadership background and strong record in driving business results. His experience includes product and brand development, commercialization, business development and alliance management across pharmaceutical, device and diagnostic businesses. Since joining Eisai in July 2022, he has led the development and implementation of the commercial launch and growth strategy for the company’s U.S. Alzheimer’s disease (AD) business, following the accelerated approval of a compound by the FDA in January 2023 and then its traditional approval in July 2023.

Prior to Eisai, Mr. Fagan served as Chief Operating Officer at VMS Biomarketing, Inc., a specialty clinical educator firm, where he directly oversaw field nurse educator teams, as well as digital engagement and IT platform, data and analytics, process operations and compliance. Prior to this position, he spent a significant portion of his career at Eli Lilly & Company, where he began in corporate finance then held progressive roles in sales, marketing, and related commercial functions, including seven years in roles dedicated to AD. As Global Commercial Leader, Alzheimer’s Disease, he designed, built and led commercial teams to launch a first-in-class PET radiopharmaceutical used in the diagnosis of AD. He also served as Eli Lilly’s Global Brand Development Leader for AD, in which he was the commercial lead on an alliance for an FDA-approved product for the treatment of early AD.

Mr. Fagan earned his Master of Business Administration (MBA) in general management from Stanford University. He holds a Bachelor of Arts degree in Economics from DePauw University, where he graduated summa cum laude and is a member of Phi Beta Kappa.

Read more

This Speaker's Sessions

Tuesday Oct. 17
2:30–3:15 PM ET
Watch Replay
Now Live!

New Technologies for Early Detection and Diagnosis of Alzheimer’s

Scaling up technologies for early detection of Alzheimer’s pathology and cognitive impairment promises to transform the global response to Alzheimer’s disease. Digital biomarkers and fluid biomarkers (ranging from cerebrospinal fluid to blood) to detect the disease are advancing rapidly in clinical practice and will enable a more simple, timely, and accurate Alzheimer’s diagnosis.  Key Question: What do these tools and technologies mean for patients and their doctors?

View SessionWatch Replay